Home / Recalls / MACLEODS PHARMA USA, INC / D-0403-2026

D-0403-2026 Class II Ongoing

Recalled by MACLEODS PHARMA USA, INC — Princeton, NJ

Recall Details

Product Type
Drugs
Report Date
April 1, 2026
Initiation Date
February 26, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1315 bottles

Product Description

Levothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Sarigam, Valsad, Guajarat, INDIA NDC 33342-401-44

Reason for Recall

Subpotent Drug

Distribution Pattern

Nationwide

Code Information

Lot 16240062A, exp date 3/2026

Other recalls by MACLEODS PHARMA USA, INC

  • D-0498-2024 Class II — Losartan Potassium and Hydrochlorothiazide Tablets, USP 50mg /12.5 mg, 1000-coun (May 7, 2024)
  • D-0162-2023 Class III — Levofloxacin Tablets, USP 500 mg; 50-count bottles, Rx Only, Manufactured for: M (January 5, 2023)
  • D-1174-2022 Class II — Eszopiclone Tablets, USP 1 mg, packaged in 30-count bottles, Rx Only, Manufactu (June 16, 2022)
  • D-1164-2022 Class II — Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 cou (June 10, 2022)
  • D-0832-2022 Class II — Losartan Potassium Tablets, USP, 25 mg, a) 90-count bottles (NDC # 33342-044-10) (April 15, 2022)
  • D-0834-2022 Class II — Losartan Potassium Tablets, USP, 100 mg, a) 30-count bottles (NDC # 33342-046-07 (April 15, 2022)
  • D-0833-2022 Class II — Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottles (NDC # 33342-045-07) (April 15, 2022)
  • D-0835-2022 Class II — Losartan Potassium & Hydrochlorothiazide Tablets, USP, 50 mg/12.5 mg, a) 30-coun (April 15, 2022)
  • D-0837-2022 Class II — Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/12.5 mg, a) 30-cou (April 15, 2022)
  • D-0836-2022 Class II — Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/25 mg, a) 30-count (April 15, 2022)